바이오로직스 자료
Accelerating the development and production of high quality bispecific antibodies
Bispecific antibodies (bsAbs) hold great therapeutic potential but face challenges in development and manufacturing due to their complex structure. Samsung Biologics' S-DUAL™ platform tackles these hurdles by enhancing productivity and quality through innovative design.
In this whitepaper, we explore how an upstream process optimization initiative led to increased productivity and improved commercialization readiness of bsAb programs, resulting in reduced development timeline and cost.
Bispecific antibodies (bsAbs) hold great therapeutic potential but face challenges in development and manufacturing due to their complex structure. Samsung Biologics' S-DUAL™ platform tackles these hurdles by enhancing productivity and quality through innovative design.
In this whitepaper, we explore how an upstream process optimization initiative led to increased productivity and improved commercialization readiness of bsAb programs, resulting in reduced development timeline and cost.